Related Experiment Video
Updated: Aug 9, 2026
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with
1Department of Internal Medicine, Department of Nephrology, Faculty of Medicine, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey. elifdizen@hotmail.com.
Objective:
We aimed to investigate the prognostic values of systemic immune inflammation index and pan-immune inflammation value in patients with idiopathic low and moderate risk membranous nephropathy.
Patients And Methods:
All membranous nephropathy patients diagnosed in the nephrology clinic between January 2015 and January 2022 were reviewed retrospectively. Patients with idiopathic membranous nephropathy were included. The patients were divided into two groups; the complete remission group: whose proteinuria decreased below 0.3 g/day and serum albumin level above 3.5 g/dL after 6 months of conservative treatment, and the non-remission group: all other patients. Groups were compared in terms of systemic immune inflammation index and pan-immune inflammation value.
Results:
Patients in the non-remission group had significantly higher systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) than patients in the complete remission group (p<0.05). An SII of 1,056.2 was found to have 63.6% sensitivity and 100% specificity in predicting non-remission, and a PIV of 447.4 was found to have 100% sensitivity and 70.6% specificity in predicting non-remission.
Conclusions:
SII and PIV are reliable markers for predicting non-remission in patients with low and moderate risk idiopathic MN.
Insights
Systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV) can predict non-remission in idiopathic membranous nephropathy patients. Higher SII and PIV levels indicate a lower likelihood of remission in these patients.
Area of Science:
- Nephrology
- Immunology
- Biomarkers
Background:
- Idiopathic membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
- Predicting remission in low and moderate-risk MN is crucial for guiding treatment strategies.
- Novel biomarkers are needed to improve prognostic accuracy.
Purpose of the Study:
- To evaluate the prognostic value of the systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV) in patients with idiopathic low and moderate-risk membranous nephropathy.
- To determine if SII and PIV can predict complete remission versus non-remission.
Main Methods:
- Retrospective review of idiopathic MN patients diagnosed between January 2015 and January 2022.
- Patients were categorized into complete remission (proteinuria <0.3 g/day, serum albumin >3.5 g/dL after 6 months) and non-remission groups.
- Comparison of SII and PIV between the two groups.
Main Results:
- Patients in the non-remission group exhibited significantly higher SII and PIV compared to the complete remission group (p<0.05).
- An SII cutoff of 1,056.2 demonstrated 63.6% sensitivity and 100% specificity for predicting non-remission.
- A PIV cutoff of 447.4 showed 100% sensitivity and 70.6% specificity for predicting non-remission.
Conclusions:
- The systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV) serve as reliable predictors of non-remission in low and moderate-risk idiopathic MN.
- These inflammatory markers can aid in risk stratification and personalized treatment approaches for MN patients.
More Related Videos
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:12Chronic Inflammation: Introduction